Pharming completes GRAS filing for hLF
Netherlands-based biotechology company Pharming NV says that it has completed its human lactoferrin (hLF) filing for a Generally Recognized as Safe notification with the US Food and Drug Administration.
Pharming has notified the FDA that its hLF is generally recognized as safe for use as an ingredient in functional foods. Pharming's hLF GRAS notification has been reviewed by an independent scientific expert panel. After careful evaluation of numerous safety studies performed with Pharming's hLF, as well as of published scientific data, the expert panel concluded that hLF is safe for its intended uses, the company notes.
"Pharming is pleased with the progress on the development of hLF," said Francis Pinto, the firm's chief executive, adding: "the company is in a strong position to execute commercial agreements and is ready for a new phase of rapid corporate growth."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze